Please assess the completion status of the following clinical trial:

Trial Title: Bronchodilatory Efficacy of a Single Dose QMF149 (Indacaterol Maleate/Mometasone Furoate) Via the Twisthaler® Device in Adult Patients With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female adult patients aged 18-75 years with persistent asthma~* Patients with persistent asthma, diagnosed according to the Global Initiative for Asthma guidelines (GINA) and who additionally met the following criteria:~  1. Patients receiving daily treatment with inhaled corticosteroid up to the maximum dose per day indicated in the package leaflet, in a stable regimen for the month prior to Visit 1.~ 2. Patients with a forced expiratory volume in 1 second (FEV1) at Visit 1 of ≥ 50% of the predicted normal value. This criterion for FEV1 had to be demonstrated after a washout period of at least 6 hours during which no short acting β2-agonist had been inhaled, and a minimum of 48 hours for a long acting β2-agonist.~ 3. Patients who demonstrated an increase of ≥12% and ≥200 mL in FEV1 over their pre-bronchodilator value 30 minutes after inhaling a total of 200 μg of salbutamol (or albuterol) via metered dose inhaler (MDI) (the reversibility test). Reversibility had to be demonstrated after an appropriate washout period of at least 6 hrs prior to the evaluation for a shortacting β2-agonist. The administration of salbutamol (or albuterol) for the reversibility test was to be within 30 minutes after pre-bronchodilator spirometry. Reversibility had to be demonstrated at Visit 1 or between Visits 1 and 2, in order for patients to be included in the trial.~ 4. For each patient, the smaller value of the Visit 1 FEV1 or the Visit 2 FEV1 pre-dose value had to be at least 85% of the larger value.~* Body mass index (BMI) between 18 and 32 kg/m\^2 and weight \>50 kg.~* patients using local contraception~Exclusion Criteria:~* Pregnant or nursing women~* Recent use of tobacco or history of smoking \> 10 pack years~* Patients diagnosed with chronic obstructive pulmonary disease (COPD)~* Patients with recent experience of severe asthma attack/exacerbation within 6-months of study start~* Patients with frequent rescue medication (\>8 puffs/day for two consecutive days)~* Clinically relevant laboratory abnormality or a clinically significant condition~* Active cancer or a history of cancer with less than 5 years disease free survival time~* History of long QT syndrome or with long QTc interval prior to dosing~* History of hypersensitivity to the study drugs or to drugs with similar chemical structures~* Use of certain medications~* Use of other investigational drugs~* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result~* History of immunodeficiency diseases, including a positive human immumodeficiency virus (HIV) test result.~* History of drug or alcohol abuse or evidence of such abuse~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Indacaterol/mometasone - Placebo (Type: EXPERIMENTAL): In Treatment Period 1 (Day 1) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg once a day in the morning via the Twisthaler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of placebo via the Twisthaler device once a day in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.
- Placebo - indacaterol/mometasone (Type: EXPERIMENTAL): In Treatment Period 1 (Day 1) participants received 2 inhalations of placebo in the morning via the Twistheler device. In Treatment Period 2 (Day 8) participants received 2 inhalations of indacaterol maleate 250 μg / mometasone furoate 200 μg via the Twisthaler device in the morning. In Treatment Period 3 (Day 15) participants received fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg twice a day delivered via dry-powder inhaler. Each treatment period was separated by a minimum washout period of 7 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).